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Abstract
Rationale 3,4-Methylenedioxymethamphetamine (MDMA,
ecstasy) increases sociability. The prosocial effects of MDMA
may result from the release of the “social hormone” oxytocin
and associated alterations in the processing of socioemotional
stimuli.
Materials and methods We investigated the effects ofMDMA
(125 mg) on the ability to infer the mental states of others from
social cues of the eye region in the Reading the Mind in the
Eyes Test. The study included 48 healthy volunteers (24 men,
24 women) and used a double-blind, placebo-controlled,
within-subjects design. A choice reaction time test was used
to exclude impairments in psychomotor function. We also
measured circulating oxytocin and cortisol levels and subjec-
tive drug effects.
Results MDMA differentially affected mind reading depend-
ing on the emotional valence of the stimuli. MDMA enhanced
the accuracy of mental state decoding for positive stimuli (e.g.,
friendly), impaired mind reading for negative stimuli (e.g.,
hostile), and had no effect on mind reading for neutral stimuli
(e.g., reflective). MDMA did not affect psychomotor perfor-
mance, increased circulating oxytocin and cortisol levels, and
produced subjective prosocial effects, including feelings of
being more open, talkative, and closer to others.
Conclusions The shift in the ability to correctly read socio-
emotional information toward stimuli associated with positive
emotional valence, together with the prosocial feelings elicited
by MDMA, may enhance social approach behavior and so-
ciability when MDMA is used recreationally and facilitate
therapeutic relationships in MDMA-assisted psychotherapeu-
tic settings.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)
increases empathic feelings and sociability (Bedi et al. 2009,
2010; Dumont et al. 2009). The prosocial effects of MDMA
could result from the emotional interoceptive effects of the
drug but also from the altered perception or processing of
social signals. For example, acute administration of MDMA
in ecstasy users decreased the accuracy of facial fear recogni-
tion (Bedi et al. 2010), attenuated responses to threatening
faces in the amygdala (Bedi et al. 2009), and enhanced
responses to happy expressions in the ventral striatum (Bedi
et al. 2009). Thus, MDMAmay increase sociability by reduc-
ing recognition and responses to threatening social stimuli and
enhancing responses to rewarding stimuli. Here, we evaluated
whether MDMA also alters the ability to identify more com-
plex emotions assessed with the Reading the Mind in the Eyes
Test (RMET).
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The neurochemical mechanisms that underlie the social
effects of MDMA are largely unexplored. The social neuro-
peptide oxytocin is a key regulator of emotional and social
behavior (Meyer-Lindenberg et al. 2011; Neumann 2008) and
may mediate the social effects of MDMA. In fact, in rats,
MDMA has been shown to activate oxytocin-containing neu-
rons in the hypothalamus (Thompson et al. 2007), release
oxytocin from the hypothalamus (Forsling et al. 2002), and
increase plasma levels of oxytocin (Thompson et al. 2007).
MDMA increased social interaction in male rats (Thompson
et al. 2007, 2009), an effect blocked by intraventricular admin-
istration of an oxytocin receptor antagonist (Thompson et al.
2007). MDMA also elevated plasma concentrations of oxyto-
cin in humans (Dumont et al. 2009; Wolff et al. 2006).
Oxytocin has been shown to improve mind reading in the
RMET (Domes et al. 2007b; Guastella et al. 2010). MDMA
releases oxytocin and may similarly improve performance in
the RMET. However, in other tests, oxytocin selectively im-
proved the recognition of happy facial expressions but impaired
the decoding of negative facial expressions (Di Simplicio et al.
2009; Marsh et al. 2010). We therefore explored whether
MDMA differentially interferes with the ability to decode com-
plex emotions in the RMET depending on the emotional va-
lence of the stimuli.
MDMA releases norepinephrine, serotonin, and dopa-
mine from nerve terminals via their corresponding mono-
amine transporter (Rothman et al. 2001). To explore the
mechanism of action of MDMA, we investigated the effects
of three pretreatments on the response to MDMA. We used
the norepinephrine transporter inhibitor reboxetine to block
the MDMA-induced release of norepinephrine (Hysek et al.
2011). The dual serotonin and norepinephrine transporter
inhibitor duloxetine was used to block the MDMA-induced
release of both serotonin and norepinephrine (Simmler et al.
2011a). Clonidine was used to block any MDMA-induced
transporter-independent vesicular release of norepinephrine
(Hysek et al. 2012).
Materials and methods
Study design
This was a prospectively designed pooled analysis of three
double-blind, placebo-controlled, randomized, within-subjects
studies (Hysek et al. 2011, 2012; Simmler et al. 2011a, b). The
pre-specified primary endpoint of the pooled analysis was to
demonstrate an effect of MDMA on RMET performance
compared with placebo in 48 subjects. All subjects included
in the three studies received MDMA, placebo, one of three
different pretreatments prior to MDMA, or the pretreatment
alone (Fig. 1). Thus, the four experiential conditions for all
subjects were placebo-placebo, pretreatment-placebo, placebo-
MDMA, and pretreatment-MDMA in balanced order. Of
the 48 subjects, 16 (eight male, eight female) received the
serotonin-norepinephrine transport inhibitor duloxetine as pre-
treatment, 16 (eight male, eight female) received the norepi-
nephrine transport inhibitor reboxetine as pretreatment, and 16
(eight male, eight female) received the α2 adrenergic receptor
agonist clonidine as pretreatment. The random allocation se-
quence was developed by a clinical pharmacist and concealed
from all individuals involved in study management. The wash-
out periods between sessions were ≥10 days. The studies were
conducted in accordance with the Declaration of Helsinki and
the International Conference on Harmonization Guidelines on
Good Clinical Practice and approved by the Ethics Committee
of the Canton of Basel, Switzerland. The use of MDMA in
healthy subjects was authorized by the Swiss Federal Office of
Public Health, Bern, Switzerland. The studies were registered
at ClinicalTrials.gov (NCT00886886, NCT00990067, and
NCT01136278). Target sample size of the pooled study was
based on the effects of oxytocin in the RMET in previous
studies (Domes et al. 2007b; Guastella et al. 2010). The sample
size of the individual studies was based on power analyses
indicating that 13 subjects would be needed to detect a reduc-
tion of 20% in the subjective effects of MDMA (the primary
outcome) by the pretreatments with more than 80% power
using a within-subjects study design. Test sessions took place
in a quiet hospital research ward with no more than two
research subjects present per session.
Volunteers
Forty-eight healthy subjects (24 men, 24 women) aged 18 to
44 years (mean ± SD, 26 ± 5 years) and with a body weight
of 68 ± 11 kg were recruited on the university campus.
The exclusion criteria included the following: (1) age <18
or >45 years, pregnancy determined by a urine test before each
test session; (2) body mass index <18.5 or >25 kg/m2; (3)
personal or family (first-degree relative) history of psychiatric
disorder (determined by the structured clinical interview for
axis I and axis II disorders according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (Wittchen
et al. 1997) supplemented by the SCL-90-R Symptom Check-
list (Derogatis et al. 1976; Schmitz et al. 2000), Freiburg
Personality Inventory (Fahrenberg et al. 1984), and Trait Scale
of the State-Trait Anxiety Inventory (Spielberger et al. 1970);
(4) the regular use of medications; (5) chronic or acute physical
illness assessed by physical examination, electrocardiogram,
standard hematology, and chemical blood analyses; (6) smok-
ing more than 10 cigarettes per day; (7) a lifetime history of
using illicit drugs more than five times, with the exception of
cannabis; (8) illicit drug use within the last 2 months; and (9)
illicit drug use during the study determined by urine tests
conducted before the test sessions using TRIAGE 8 (Biosite,
San Diego, CA, USA). The subjects were asked to abstain from
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excessive alcohol consumption between test sessions and limit
alcohol use to one glass on the day before each test session. All
of the subjects were nonsmokers. Thirty-six subjects had pre-
viously used cannabis. Fourteen subjects reported using illicit
drugs (one to four times). Four subjects had tried ecstasy, two
had tried lysergic acid diethylamide, seven had tried psilocybin,
four had tried cocaine, and one had tried amphetamine. Impor-
tantly, 44 subjects were MDMA-naive. Female subjects were
investigated during the follicular phase (days 2–14) of their
menstrual cycle to account for the potential confounding effects
of sex hormones and cyclic changes in the reactivity to amphet-
amines (White et al. 2002). All of the subjects provided their
written informed consent before participating in the study, and
they were paid for their participation.
Measures
Reading the Mind in the Eyes Test (RMET)
The RMET (Baron-Cohen et al. 2001) was used to assess
the identification of complex emotions 90 min after the
administration of 125 mg MDMA or identical placebo.
The RMET was originally developed to assess the social
cognitive abilities of high functioning individuals with au-
tism spectrum disorder (Baron-Cohen et al. 2001). In the
RMET, 36 pictures of the eye region of faces are presented
on a computer screen, and participants are asked to decide
which of four words best describes what the person in the
picture is thinking or feeling (Baron-Cohen et al. 2001).
RMET scores are calculated as the total number of correct
discriminations of all 36 items. Additionally, subscores in the
present study were computed for positive (eight items), neg-
ative (12 items), and neutral (16 items) emotional valence as
previously described (Harkness et al. 2005) and used by others
(Fertuck et al. 2009).
Choice reaction time task (CRTT)
We used an adaptive five CRTT to assess potential drug
effects on sustained attention and executive motor function
(Schachinger et al. 2003). In this test, the subjects had to
respond to the presentation of five different colored lights by
pressing the button with the corresponding color as quickly
and accurately as possible (Schachinger et al. 2003). A
training run was performed before the first baseline assess-
ment and data were analyzed as drug-induced changes from
baseline to correct for training effects (Haschke et al. 2010).
The CRTT was performed before and 120 min after admin-
istration of MDMA or placebo in 32 subjects. The task is
sensitive to benzodiazepine administration (Haschke et al.
2010).
Endocrine measures
Blood samples for the determination of plasma oxytocin and
cortisol levels were collected in 32 and 48 subjects before and
120 min after drug administration, respectively. Plasma oxyto-
cin concentrations were determined using a radioimmunoassay
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Fig. 1 Study diagram
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in the Neurobiology Department (Inga D. Neumann),
University of Regensburg, Germany, as previously described
(Landgraf et al. 1995). Plasma cortisol concentrations were
determined using an automated solid-phase chemilumines-
cence immunoassay (Immulite 2000 Cortisol, Siemens Med-
ical Solutions Diagnostics, Los Angeles, CA, USA).
Subjective effects
Subjective effects were assessed using the Addiction Re-
search Center Inventory (ARCI) (Martin et al. 1971) and
visual analog scales (VASs) (Hysek et al. 2011). The ARCI
is a true–false questionnaire with five empirically derived
scales (Martin et al. 1971). The Amphetamine scale is
sensitive to the effects of d-amphetamine, the Benzedrine
Group scale is a stimulant scale consisting mainly of items
relating to intellectual efficiency and energy, the Morphine-
Benzedrine Group scale is a measure of euphoria, the
Pentobarbital-Chlorpromazine-Alcohol Group scale is a mea-
sure of sedation, and the Lysergic Acid Diethylamine Group
scale is a measure of dysphoria and somatic symptoms. The
ARCI has previously been shown to be sensitive to the effects
ofMDMA (Farre et al. 2007; Tancer and Johanson 2007). The
ARCI was used in its validated German version (Bopp et al.
2005) before and 2.5 and 5 h after drug administration. Visual
analog scores were used to assess “any drug effects” and
prosocial effects, including “closeness to others,” “open,”
and “talkative.” VASs were presented as 100 mm horizontal
lines marked from “not at all” on the left to “extremely” on the
right. VASs assessing prosocial feelings were bidirectional
(±50 mm). VAS scores were assessed before and 0,
0.33, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 h after drug
administration. The study included additional pharmacody-
namic and pharmacokinetic outcomes as reported elsewhere
(Hysek et al. 2011, 2012; Simmler et al. 2011a, b). All out-
come measures were assessed identically and at the same time
points following MDMA or placebo administration across
all three studies.
Drugs
(±) MDMA hydrochloride (Lipomed AG, Arlesheim,
Switzerland) was obtained from the Swiss Federal Office of
Public Health and prepared as gelatin capsules (100 and
25 mg). Identical placebo (lactose) capsules were prepared.
MDMA was administered in a single absolute oral dose of
125 mg. This dose of MDMA corresponds to a typical recre-
ational dose or the dose of MDMA used as an adjunct to
psychotherapy (Mithoefer et al. 2010). In the reboxetine-
MDMA study, reboxetine (8 mg, Edronax; Pfizer, Zurich,
Switzerland) or identical placebo (lactose) was administered
at 20:00 hours the day before the test session and again at 7:00
hours on the test day. MDMA or placebo was administered at
8:00 hours, 1 and 12 h after reboxetine. In the duloxetine-
MDMA study, duloxetine (120 mg, Cymbalta, Eli Lilly,
Vernier, Switzerland) or identical placebo (lactose) was ad-
ministered at 20:00 hours the day before the test session and
again at 8:00 hours on the test day. MDMA or placebo was
administered at 12:00 hours, 4 and 16 h after duloxetine.
Reboxetine and duloxetine were administered twice in high
doses to obtain plasma concentrations similar to those reached
with chronic daily administrations of the drugs and as previ-
ously used to manipulate the norepinephrine function in
healthy subjects (Roelands et al. 2008). In the clonidine-
MDMA study, clonidine (150 μg, Catapresan; Boeringer
Ingelheim, Basel, Switzerland) or identical placebo (lactose)
was administered at 8:00 hours, 1 h before MDMA or
placebo (9:00 hours). Clonidine has previously been
shown to produce sympatholytic effects in this dose in healthy
subjects (Anavekar et al. 1982; Nieuwenhuis et al. 2007). The
pretreatment times used for the three drugs resulted in maxi-
mal plasma concentrations of the pretreatments at the time of
the maximal effect of MDMA (Hysek et al. 2011, 2012). On
the test days, oral drug administration was supervised by study
personnel. Compliance with the first administration of rebox-
etine and duloxetine in the evening prior to the test day was
confirmed analytically in plasma (Hysek et al. 2011; Simmler
et al. 2011a).
Statistical analyses
For the statistical analyses, data from the three studies were
pooled, and endocrine measures and reaction times were
transformed to differences from baseline. Peak effects
(Emax) were determined for repeated measures. Emax values
and RMET scores were compared using one-way General
Linear Model repeated-measures analysis of variance
(ANOVA) with drug (MDMA vs. placebo) as a factor using
STATISTICA 6.0 (StatSoft, Tulsa, OK, USA). Data from
the three substudies on all four treatment conditions were
assessed using ANOVAs, with drug (placebo-placebo,
placebo-MDMA, pretreatment-placebo, and pretreatment-
MDMA) as a factor, followed by the Tukey post hoc test.
Sequence effects were tested by including treatment order as a
factor. Potential associations between MDMA-induced endo-
crine changes and subjective effects or RMET accuracy were
assessed using Spearman’s rank correlations. The criterion for
significance was p<0.05.
Results
RMET
As shown in Fig. 2, MDMA improved mind reading perfor-
mance in the RMET for stimuli with a positive emotional
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valence (F1, 4705.13, p<0.05) and impaired performance for
stimuli with a negative emotional valence (F1, 4707.05, p<
0.01). Improvements in reading positive emotions were seen
in 40 of the 48 participants, and impairments in reading
negative emotions were seen in 38 of the 48 participants.
MDMA had no effect on the accuracy of mind reading for
emotionally neutral stimuli or the total performance score.
There were no sex differences. No statistically significant
main effects of sequence and no sequence×drug interaction
were found, excluding sequence effects of treatment on test
performance. Drug effects on the RMET in each of the three
studies are shown in Tables 2, 3, and 4. MDMA consistently
exerted similar effects on mind reading in each of the three
studies as in the pooled analysis, but the effects did not reach
statistical significance. Duloxetine nonsignificantly attenuated
the effects of MDMA on RMET performance. Similar weak
and nonsignificant reductions of the MDMA effect were also
observed for reboxetine and clonidine.
CRTT
MDMA did not alter reaction time in the CRTT (Table 1)
or the RMET (F1, 4701.8, p0NS). In the individual
studies, none of the drugs altered reaction time in the CRTT
(Tables 2, 3 and 4).
Endocrine effects
MDMA increased plasma levels of oxytocin (F1, 3108.00, p<
0.01) and cortisol (F1, 470110, p<0.001) compared with
placebo (Table 1). In the duloxetine-MDMA study sample,
duloxetine reduced the MDMA-induced increase in plasma
levels of oxytocin and cortisol (Table 3). Neither reboxetine
nor clonidine significantly affected the endocrine effects of
MDMA (Tables 2 and 4).
Subjective effects
MDMA increased scores on the Amphetamine Group, Ben-
zedrine Group, Morphine-Benzedrine Group, Pentobarbital-
Chlorpromazine-Alcohol Group, and LSDGroup scales of the
ARCI compared with placebo (F1, 47036.4, 5.1, 44.7, 36.4,
and 15.2, respectively; all p<0.001, with the exception of the
Benzedrine Group [p<0.05]; Table 1). MDMA also increased
VAS scores for “any drug effect,” “closeness,” “open,” and
“talkative” (F1, 4701183, 98.0, 105, and 105, respectively; all
p<0.001; Table 1). The endocrine effects of MDMAwere not
associated with the subjective effects of MDMA or perfor-
mance on the RMET (all rs<0.28, all p>0.1). Duloxetine
reducedMDMA-induced increases in all VAS scores (Table 3).
Duloxetine also reduced the effect of MDMA on the
Amphetamine and Morphine-Benzedrine Group scales,
which were the only scales that showed significant
effects of MDMA in the ARCI in the duloxetine-MDMA
study (Table 3). In the reboxetine-MDMA study, reboxetine
loweredMDMA-induced increases in the VAS scores for “any
drug effects” and “closeness” (Table 2). The effects of
MDMA on all subscales of the ARCI were nonsignificantly
lower after reboxetine administration. In contrast, clonidine
had no effect on the subjective response to MDMA in the
clonidine-MDMA study (Table 4). No severe adverse effects
were reported.
Discussion
The main finding of the present study was that MDMA
improved performance on the RMET for positive stimuli
and impaired performance for negative stimuli, indicating that
MDMA differentially affected the ability to correctly decode
social facial stimuli depending on the emotional valence of the
Fig. 2 MDMA had differential effects on performance in the Reading
the Mind in the Eyes Test (RMET) depending on the emotional valence
of the stimuli. MDMA increased the ability in affective mind reading
for expressions with a positive emotional valence (positive items, *p<
0.05) and impaired mind reading for negative items (**p<0.01) com-
pared to placebo. MDMA did not alter performance for neutral items or
the total score (all items). Values are mean ± SEM accuracy (percentage
of correct items) in 48 subjects
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stimulus. In a party setting, the use of MDMA may therefore
improve the correct reading of positive facial expressions and,
combined with elevated mood and extroversion, may lead to
higher approach behavior and sociability. In contrast, the
misreading of negative social information as being more neu-
tral or positive may result in higher social risk behavior. When
Table 1 Mean ± SEM
values for endocrine,
psychomotor, and subjective
effects of MDMA (n048)
*p<0.05, **p<0.01,
***p<0.001 compared
to placebo
Placebo MDMA
Hormones
Oxytocin (Δ pg/mL) 5.0±3.9 28.1±4.0**
Cortisol (Δ nmol/L) −262.0±27.1 174.5±29.8***
Choice reaction time test (CRTT)
Reaction time (Δ ms) 4.6±3.7 −1.7±6.1
Addiction Research Inventory (ARCI)
Amphetamine −0.1±0.1 2.4±0.4***
Benzedrine Group 0.6±0.18 1.3±0.3*
Morphine-Benzedrine Group 0.2±0.2 5.5±0.8***
Pentobarbital-Chlorpromazine-Alcohol Group 0.2±0.2 3.0±0.5***
LSD Group 0.5±0.2 2.1±0.4***
Visual analog scales
Any drug effect 2.2±1.3 87.2±2.4***
Closeness 0.2±0.2 28.2±2.8***
Open 0.8±0.4 30.9±2.4***
Talkative 0.6±0.3 26.7±2.6***
Table 2 Mean ± SEM values and statistics for the reboxetine-MDMA study (n016)
Placebo-Placebo Reboxetine-Placebo Placebo-MDMA Reboxetine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) NA NA NA NA
Cortisol (Δ nmol/L) −203±46 −230±60### 245±47*** 144±60*** 21.86 0.001
Reading the Mind in the Eyes Test
Total score 0.679±0.03 0.679±0.03 0.649±0.03 0.684±0.03 0.99 NS
Positive items 0.719±0.04 0.688±0.04 0.734±0.06 0.727±0.04 0.46 NS
Negative items 0.630±0.06 0.599±0.05 0.552±0.05 0.615±0.04 1.44 NS
Neutral items 0.695±0.04 0.734±0.04 0.680±0.04 0.715±0.04 1.19 NS
Choice reaction time task
Mean reaction time (ms) 4.5±5.7 16.1±8.5 0.42±13.3 21.9±10.1 1.23 NS
Addiction Research Center Inventory
Amphetamine 0.2±0.1 0.4±0.3## 4.1±0.9*** 3.3±0.6** 12.04 0.001
Benzedrine Group 1.1±0.4 0.7±0.3# 2.5±0.4 1.7±0.5 5.74 0.05
Morphine-Benzedrine Group 0.4±0.2 0.7±0.5### 8.4±1.3*** 5.4±1.1** 19.33 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.6±0.2 1.4±0.6## 4.4±0.9*** 3.1±0.7** 9.18 0.001
LSD Group 0.7±0.2 0.9±0.3### 4.3±0.8*** 2.8±0.6* 10.4 0.001
Visual analog scales
Any drug effect 1.9±1.3 8.0±3.4 85±4.8*** 68±6.2***,## 120.40 0.001
Closeness 0.3±0.2 0.0±0.0### 34±5.9*** 21±4.5***,# 22.66 0.001
Open 1.0±0.8 4.2±2.2### 30±3.1*** 23±4.9 22.73 0.001
Talkative 0.5±0.4 2.2±1.3### 26±4.3*** 20±5.1 18.56 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
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MDMA is administered during psychotherapy to treat post-
traumatic stress disorder (Mithoefer et al. 2010), the MDMA-
induced shift in accuracy toward a better perception of posi-
tive emotional stimuli may facilitate the therapeutic alliance
(Johansen and Krebs 2009).
MDMA did not affect total RMET score or the decoding of
stimuli with neutral emotional valence. Thus, MDMA did not
improve mind reading overall. Our finding in mostly non-
ecstasy-experienced volunteers is consistent with a previous
work, in which MDMA did not alter performance on the
RMET in 21 ecstasy users (Bedi et al. 2010). The latter study
did not evaluate whether emotional valence modulates the
effect of MDMA on the RMET. However, in another test in
the same study, MDMA differentially reduced the accurate
identification of negative, threat-related facial signals but did
not affect the identification of neutral or positive emotions
(Bedi et al. 2010). The emotion-specific effect of MDMA on
the decoding of facial expressions suggests that MDMA may
differentially affect brain areas involved in the processing of
emotional information. Indeed, functional magnetic resonance
imaging showed that MDMA attenuated the response to angry
faces in the amygdala, a structure activated by negative social
signals and fear (Zald 2003), and enhanced the response to
happy faces in the ventral striatum (Bedi et al. 2009), a structure
activated by reward expectation (Knutson and Cooper 2005).
Altogether, the data indicate that MDMA lowers reactivity to
negative social stimuli, such as threat, and enhances responding
to positive social stimuli, such as a smile.
We found that MDMA increased plasma levels of oxyto-
cin, confirming a placebo-controlled MDMA study (Dumont
et al. 2009) and observations in clubbers following the use of
ecstasy pills (Wolff et al. 2006). Oxytocin is a candidate for
the mediation of the empathic and social effects of MDMA
(Thompson et al. 2007). For example, MDMA increased
social interaction in rats that interacted for the first time,
predominantly reflected by an increase in adjacent lying be-
havior. This effect of MDMA was reduced by pretreatment
with an oxytocin antagonist (Thompson et al. 2007). Similar
to MDMA, oxytocin also reduced activation of the amygdala
in response to threatening social stimuli (Kirsch et al. 2005),
although other work showed that oxytocin reduced amygdala
responses regardless of the emotional valence of the facial
stimuli (Domes et al. 2007a) in men and enhanced amygdala
responses to fearful stimuli in women (Domes et al. 2010),
suggesting both sex differences and more complex effects of
oxytocin on emotion processing. Particularly relevant for the
present study, intranasal oxytocin administration improved
performance on the RMET in healthy male subjects (Domes
Table 3 Mean ± SEM values and statistics for the duloxetine-MDMA study (n016)
Placebo-Placebo Duloxetine-Placebo Placebo-MDMA Duloxetine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) 1.4±7.1 1.6±4.7 22.2±9.1* 1.8±5.9# 4.56 0.01
Cortisol (Δ nmol/L) −354±46 −241±30### 157±62*** −181±29*,### 25.65 0.001
Reading the Mind in the Eyes Test
Total score 0.665±0.02 0.661±0.02 0.656±0.02 0.689±0.02 1.28 NS
Positive items 0.656±0.05 0.680±0.04 0.750±0.05 0.711±0.04 1.71 NS
Negative items 0.630±0.02 0.661±0.03 0.578±0.04 0.667±0.03 2.26 NS
Neutral items 0.695±0.02 0.641±0.04 0.668±0.05 0.695±0.04 0.70 NS
Choice reaction time task
Mean reaction time (ms) 4.7±7.1 3.4±32 −3.8±30 4.5±30 0.28 NS
Addiction Research Center Inventory
Amphetamine −0.1±0.2 −0.3±0.2 4.6±0.5*** 0.9±0.5### 35.13 0.001
Benzedrine Group 0.6±0.2 −0.1±0.3 1.4±0.4 −0.2±0.5# 4.07 0.05
Morphine-Benzedrine Group 0.5±0.5 0.6±0.2 8.4±0.9*** 2.3±0.8### 41.74 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.1±0.4 1.9±0.5 3.1±0.8 2.3±0.9 3.92 0.05
LSD Group 0.8±0.2 0.1±0.3 0.6±0.5 0.9±0.5 0.84 NS
Visual analog scales
Any drug effect 3.8±3.6 6.0±2.5 86.7±3.6*** 33±8***,### 74.47 0.001
Closeness 0.0±0.0 0.0±0.0 27.3±3.9*** 4.6±2.5### 37.32 0.001
Open 1.4±0.9 0.4±0.4 32.2±4.3*** 6.0±3.3### 36.88 0.001
Talkative 1.2±0.8 0.3±0.3 28.8±5.1*** 10.7±3.7### 21.13 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
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et al. 2007b) or male subjects with autism spectrum disorders
(Guastella et al. 2010). The effect of MDMA on the decoding
of positive emotional information in the present study might
therefore be explained by the oxytocinergic properties of
MDMA. Notably, oxytocin selectively improved the recogni-
tion of specific emotions in previous studies, similar to
MDMA in the present study. Specifically, oxytocin selectively
enhanced the recognition of happy facial expressions (Marsh
et al. 2010; Schulze et al. 2011), reduced misclassifications of
positive or ambiguous emotions as negative emotions (Di
Simplicio et al. 2009), increased the memory for positive faces
(Guastella et al. 2008), and slowed reaction times dur-
ing the recognition of negative fearful facial expressions
(Di Simplicio et al. 2009). Altogether, these data support the
hypothesis that the effects of MDMA on mind reading are
very similar to those of oxytocin and are potentially mediated
by this neuropeptide. MDMA-induced increases in the plasma
concentration of oxytocin were not correlated with RMET
performance in our study. However, plasma samples were
not available for all subjects of the study and it is also unclear
whether plasma concentrations of oxytocin reflect brain con-
centrations of this neuropeptide.
The administration of oxytocin in humans does not pro-
duce subjective mood effects. However, a drug discrimination
study showed that rats trained to respond for MDMA also
responded if MDMAwas substituted by the oxytocin receptor
agonist carbetocin, and responding for MDMA was reduced
by administration of the oxytocin receptor antagonist atosiban
(Broadbear et al. 2011). Oxytocin may therefore contribute to
the interoceptive subjective effects of MDMA. Whether the
subjective state of positive feelings and closeness to others
elicited by MDMA in humans is also associated with in-
creased emotional empathy (i.e., the sharing of experiences
of emotional states perceived in others) remains to be tested.
The finding that MDMA did not improve overall perfor-
mance on the RMET in the present study and a previous
study (Bedi et al. 2010) and the lack of improved face or
vocal affect recognition (Bedi et al. 2010) suggest that
MDMA does not improve cognitive empathy overall (i.e., the
recognition of emotional states in others). Oxytocin has
recently been shown to increase emotional but not cog-
nitive empathy in healthy male volunteers (Hurlemann
et al. 2010). We did not assess the effects of MDMA on
emotional empathy. Studies on the effects of MDMA on
different measures of emotional and cognitive empathy are
needed.
In the present study, MDMA also increased plasma levels
of cortisol, consistent with previous studies (Harris et al.
Table 4 Mean ± SEM values and statistics for the clonidine-MDMA study (n016)
Placebo-Placebo Clonidine-Placebo Placebo-MDMA Clonidine-MDMA F3, 45 0 p <
Hormones
Oxytocin (Δ pg/mL) 9.2±6.3 12.1±12.4 33.9±3.4* 20.2±5.5 3.32 0.05
Cortisol (Δ nmol/L) −229±42 −241±43 122±42 190±36*** 37.02 0.001
Reading the Mind in the Eyes Test
Total score 0.69±0.03 0.698±0.02 0.684±0.03 0.698±0.03 0.16 NS
Positive items 0.62±0.05 0.641±0.04 0.695±0.05 0.656±0.05 0.88 NS
Negative items 0.69±0.04 0.641±0.04 0.620±0.05 0.661±0.04 1.12 NS
Neutral items 0.73±0.04 0.770±0.02 0.727±0.04 0.746±0.03 0.54 NS
Choice reaction time task
Mean reaction time (ms) NA NA NA NA
Addiction Research Center Inventory
Amphetamine −0.4±0.2 −0.5±0.3### 3.3±0.4*** 3.3±0.5*** 37.11 0.001
Benzedrine Group 0.1±0.2 −1.5±0.5## 0.7±0.6 0.5±0.4 5.36 0.01
Morphine-Benzedrine Group −0.4±0.4 −0.9±0.5### 7.7±1.0*** 7.4±1.0*** 46.12 0.001
Pentobarbital-Chlorpromazine-
Alcohol Group
0.1±0.4 2.7±0.7 4.6±0.7*** 4.0±0.8*** 11.08 0.001
LSD Group 0.1±0.2 0.6±0.2 1.4±0.7 1.7±0.4* 3.84 0.05
Visual analog scales
Any drug effect 0.9±0.9 16.8±6.2### 89.6±4.0*** 81.6±6.9*** 87.55 0.001
Closeness 0.4±0.4 0.0±0.0### 23.4±4.6*** 24.1±4.7*** 20.35 0.001
Open 0.0±0.0 0.0±0.0### 30.3±4.4*** 30.2±5.0*** 33.71 0.001
Talkative 0.0±0.0 0.0±0.0### 24.8±4.4*** 24.7±4.5*** 24.26 0.001
NA not assessed, NS not significant
*p<0.05, **p<0.01, ***p<0.001, compared with Placebo-Placebo; # p<0.05, ## p<0.01, ### p<0.001, compared with Placebo-MDMA
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2002; Mas et al. 1999). We did not observe any association
between cortisol levels and RMET performance, and high
stress- compared with low stress-induced cortisol elevations
in healthy subjects did not alter RMETscores in another study
(Smeets et al. 2009).
In the ARCI, MDMA produced moderate amphetamine-
type effects with only slight stimulation, pronounced euphoria,
as well as moderate alcohol-like and moderate hallucinogen-
like effects similar to earlier works (Farre et al. 2007; Tancer
and Johanson 2007). In the VAS, MDMA produced its
MDMA-typical “entactogenic” effects including closeness to
others, openness, and talkativeness as described earlier (Hysek
et al. 2011; Liechti et al. 2001). We also assessed the effects of
different pretreatments on the response toMDMA.Duloxetine,
which inhibits MDMA-induced monoamine transporter-
dependent serotonin and norepinephrine release (Simmler
et al. 2011a, b), reduced all the amphetamine-type and euphori-
genic psychotropic effects of MDMA in the ARCI, the
entactogen-like aspects of the MDMA response in all the
VAS, and also endocrine effects of MDMA. Duloxetine also
tended to attenuate the effects of MDMA on RMET, although
these trends were not statistically significant. Reboxetine,
which inhibitsMDMA-induced norepinephrine release (Hysek
et al. 2011), reduced some of the psychotropic effects in the
VAS but not the endocrine effects of MDMA. Clonidine,
which inhibits any MDMA-induced transporter-independent
vesicular release of norepinephrine (Hysek et al. 2012), had
no effect on either the subjective or endocrine response to
MDMA. The finding that inhibition of the MDMA-induced
serotonin and norepinephrine release by duloxetine was more
effective in reducing the acute MDMA effects in humans than
inhibition of the release of norepinephrine alone by reboxetine
or clonidine suggests that serotonin may be primarily respon-
sible for the acute effects of MDMA in humans. This view is
also consistent with earlier mechanistic studies in humans
(Farre et al. 2007; Liechti et al. 2000; Liechti and Vollenweider
2000; Tancer and Johanson 2007). The data also indicate a
primary role for serotonin in the effects ofMDMA on oxytocin
release, emotion identification, and MDMA’s potential proso-
cial effects.
In conclusion, the MDMA-induced shift in the ability to
detect socioemotional information, together with the proso-
cial feelings elicited by MDMA, is likely to enhance social
approach behavior and sociability when MDMA is used
recreationally. The change in the processing of emotional
information may also facilitate therapeutic relationships in
MDMA-assisted psychotherapy.
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